Why We Love Mushrooms!

Why We Love Mushrooms!

Why We Love Mushrooms

            As you can see from our products, we are big fans of all things mushrooms: mushroom art,  mushroom tees, mushroom stickers, mushroom tote bags, and more! You might be wondering, why are mushrooms important to these folks?

We believe mushrooms have a pivotal role to play in constructing a healthier and more sustainable world. In line with our vision, we are first and foremost passionate about the potential for psychedelic psilocybin mushrooms to change how we relate to ourselves, each other, and improve our mental health. You are invited to explore the increasingly vast clinical research showing the efficacy of psilocybin-assisted therapy in treating mental health below. However, it’s not just the psilocybe genus of mushrooms that we believe will play a monumental role in our future.

Mushrooms are increasingly being explored as sustainable alternatives to a myriad of common products. These include: meat alternatives (see the protein content of Chicken of the Woods), mushroom architecture (see Almpani-Lekka et al., 2021), mushroom surfboards, mushroom leather, and as decomposers of plastic. The best part? Research is just starting to scratch the surface regarding the ways mushrooms support the environment, human life, and planetary wellbeing.

Did you know we partner with counsellors and coaches that offer psychedelic support and integration services? Contact us to learn more or Join the Discovery Ink & Art community to get first access to these initiatives, as well as exclusive offers on our diversity of art and merchandise.


Clinical Research on Psilocybin-Assisted Therapy

Depression: (Carhart-Harris et al., 2021; Carhart-Harris et al., 2018; Carhart-Harris et al., 2016; Goodwin et al., 2022; Davis et al., 2021)

Anxiety: (Agin-Liebes, 2020; Reiche et al., 2018; Ross et al., 2016; Griffiths et al., 2016; Grob et al., 2011)

Migraines: (Schindler et al., 2021)

OCD: (Moreno et al., 2006)

Phantom limb pain: (Ramachandran et al., 2018)

Substance use disorder: (Johnson et al., 2014; Johnson et al., 2017; Bogenschutz et al., 2022)



Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., . . . Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166.

Almpani-Lekka, D., Pfeiffer, S., Schmidts, C., & Seo, S. (2021). A review on architecture with fungal biomaterials: the desired and the feasible. Fungal Biology and Biotechnology, 8(1). https://doi.org/10.1186/s40694-021-00124-5

Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O'Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA psychiatry, 79(10), 953–962. https://doi.org/10.1001/jamapsychiatry.2022.2096

Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., . . . Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med, 384(15), 1402- 1411. https://doi.org/10.1056/NEJMoa2032994

Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., . . . Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7), 619-627. https://doi.org/10.1016/S2215-0366(16)30065-7

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A random clinical trial. JAMA Psychiatry, 78(5), 481-489. https://doi.org/10.1001/jamapsychiatry.2020.3285  

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., Forbes, M., … Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., . . . Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 30(12), 1181-1197. https://doi.org/10.1177/0269881116675513

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116

Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of psychopharmacology (Oxford, England), 28(11), 983–992. https://doi.org/10.1177/0269881114548296

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735-1740.

Ramachandran, V., Chunharas, C., Marcus, Z., Furnish, T., & Lin, A. (2018). Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF) Neurocase, 249, 105–110.

Reiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majic, T. (2018). Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry, 81, 1-10.

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, England), 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512

Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., . . . D'Souza, D. C. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics, 18(1), 534-543.

Back to blog